Effects of agomelatine on sleep electroencephalogram parameters compared to selective serotonin reuptake inhibitors in patients with major depressive disorder: a six-week randomised, double-blind parallel group study versus comparator, followed by a double-blind optional treatment extension period up to six months

ISRCTN ISRCTN44737909
DOI https://doi.org/10.1186/ISRCTN44737909
Clinical Trials Information System (CTIS) 2006-004716-48
Protocol serial number CL3-20098-056
Sponsor Institut de Recherches Internationales Servier (France)
Funder Institut de Recherches Internationales Servier (France)
Submission date
03/04/2007
Registration date
22/06/2007
Last edited
18/04/2018
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration and not expected to be available in the future

Contact information

Dr Maria-Antonia Quera-Salva
Scientific

Hôpital Raymond Poincaré
104 boulevard Raymond Poincaré
Garches
92380
France

Study information

Primary study designInterventional
Study designSix-week randomised double-blind parallel groups study with agomelatine versus SSRI, followed by a double-blind optional treatment extension period up to six months with agomelatine versus SSRI
Secondary study designRandomised controlled trial
Study type Participant information sheet
Scientific title"Effects of agomelatine (25 to 50 mg/day) on sleep EEG parameters compared to escitalopram in patients with Major Depressive Disorder. A 6-week randomised, double-blind parallel groups study versus comparator, followed by a double-blind optional treatment extension period up to 6 months."
Study objectivesTo demonstrate that depressed patients treated with agomelatine present a greater improvement in sleep efficiency than patients treated with Selective Serotonin Reuptake Inhibitors (SSRI).
Ethics approval(s)First approval received from the local ethics committee (Comité de Protection des Personnes Ile de France VIII) on the 18/01/2007 (ref: 070101)
Health condition(s) or problem(s) studiedMajor Depressive Disorder
InterventionTherapeutic doses of agomelatine versus therapeutic doses of SSRI.
Intervention typeDrug
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Agomelatine, SSRI
Primary outcome measure(s)

Effects of agomelatine on sleep Electroencephalogram (EEG) parameters, corresponding to sleep efficiency index, compared to SSRI in patients with major depressive disorder.

Key secondary outcome measure(s)

1. Other sleep parameters
2. Subjective sleep parameters
3. Daytime performance
4. Evaluation of depression with the Hamilton rating scale for Depression (HAM-D) scale
5. Safety measured with adverse events, laboratory parameters, and Electrocardiogram (ECG) parameters

Completion date30/09/2008

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexAll
Target sample size at registration130
Key inclusion criteria1. Aged between 18 and 60 years
2. Male or female
3. Fulfilling Diagnostic and Statistical Manual of mental disorders fourth edition (DSM-IV-TR) criteria for major depressive disorder
Key exclusion criteria1. Women of childbearing potential without effective contraception as well as pregnant or breastfeeding women
2. All types of depression other than major depressive disorder
Date of first enrolment15/02/2007
Date of final enrolment30/09/2008

Locations

Countries of recruitment

  • United Kingdom
  • Australia
  • Austria
  • Brazil
  • Finland
  • France
  • Germany
  • Spain
  • Taiwan

Study participating centre

Hôpital Raymond Poincaré
Garches
92380
France

Results and Publications

Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
IPD sharing planThe datasets generated during and/or analysed during the current study will be available upon request from https://clinicaltrials.servier.com if a Marketing Authorisation has been granted after 1st January 2014.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/09/2011 Yes No
Basic results No No
Participant information sheet Participant information sheet 11/11/2025 11/11/2025 No Yes

Editorial Notes

18/04/2018: Internal review.
28/03/2018: Publication plan and IPD sharing statement updated.
25/01/2018: Publication plan and IPD sharing statement added.18/12/2017: results summary and publication reference added.